Skip to Content
COVID-19 Response and Update
Amneal
  • Corporate
  • India
  • About
        • AboutWe challenge convention so healthy can be possible
        • Our Purpose & Commitments
        • Rise Lead Succeed Culture
        • India Leadership
        • Site Locations
        • Awards & Recognition
  • Responsibility
  • Products
        • ProductsWe create essential medicines
        • OUR PORTFOLIO
          • Ophthalmology
          • Oncology
          • Diagnostics
          • Hospital
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Product Complaints
  • Careers
        • CareersHelp make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
  • Contact
Leading with Safety, Quality, and Innovation

Hospital

Patients in intensive care units (ICUs) can be at a higher risk of healthcare-acquired infections (HAIs) due to invasive procedures, immunosuppression, underlying health conditions, and increased age. We collaborate with stakeholders across the healthcare landscape to bring new products to market that help advance patient safety and quality. Our portfolio is tailored to meet the needs of healthcare providers across India and provide innovative solutions in critical care and anaesthesia.

Innovative Technology for Infection Prevention

The International Nosocomial Infection Control Consortium (INICC) recommends closed infusion systems to reduce hospital infections and combat antimicrobial resistance (AMR).1 In alignment with these recommendations, we have developed the Uniport Bag, a first-of-its-kind closed IV system being manufactured by Amneal for India, in India. Uniport is a safe IV with multipurpose single port bag offering a versatile and adaptive closed-infusion system.2 This advanced technology includes: 

  • Self-collapsibility for efficient fluid delivery
  • Easy-to-squeeze design for optimal usability
  • Transparent construction for clear visibility

This pioneering solution sets new standards for IV delivery in hospitals across India, helping reduce infection risks and improve patient safety.

Eye conditions like Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR) affect around 25% of patients with long-standing diabetes4. In 2021, about 101 million people in India were living with diabetes5. Additionally, Age-related Macular Degeneration (AMD) is common, and diabetes can worsen its progression4. Retinal Vein Occlusion (RVO), another leading cause of vision loss, is the second most common retinal vascular disorder6 DME, DR, AMD, and RVO are serious eye conditions that can cause vision loss and are often linked to diabetes or aging. Early detection and treatment can help manage them effectively and reduce their impact.

Product Catalogue
Product Catalogue
  1. Rosenthal VD, Duszynska W, Ider BE, Gurskis V, Al-Ruzzieh MA, Myatra SN, Gupta D, Belkebir S, Upadhyay N, Zand F, Todi SK. International Nosocomial Infection Control Consortium (INICC) report, data summary of 45 countries for 2013-2018, adult and pediatric units, device-associated module. American journal of infection control. 2021 Oct 1;49(10):1267-74.
  2. Amneal Press Release- Commemorating International Infection Prevention Week, P.D. Hinduja Hospital & MRC introduces the latest innovation in IV Infusion for the first time in Mumbai [October 17, 2022]
  • Privacy Notice
  • Copyright & Legal Disclaimer
  • Web Accessibility
  • NABP DDA Accreditation
  • Linkedin
  • X
  • Facebook
  • Youtube
© 2025 Amneal Pharmaceuticals LLC.
All rights reserved.